

## ♦ KTRH05

Clone ID	SeV-Ff-iPSC-	Product	Human iPS cells
	SCS_KTRH05_P9		
Source	Peripheral Blood, Human	Race	Caucasian
Passage No.	9	Gender	Female
Lot No.	Fit04KTRH05-220519	Manufacture Dates	June 6 <sup>th</sup> , 2022
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture method	Feeder-free (**1)	Grade	Clinical grade
Reprograming	Sendai-virus		
method			
Use and Provision	Please visit our web site for details ;		
of this cell stock	https://www.cira-foundation.or.jp/e/project/stock.html		

<sup>(%1)</sup> Reference; Nakagawa, et. al., Nat Biotechnol. 2008 26(1):101-106

## **Test Result**


Test	Method	Result
Sterility	Direct inoculation method	Negative
Mycoplasma	qPCR	Negative
Endotoxin	LAL	≤ 5 EU/mL
Virus		
(HBV, HCV, HIV, HTLV,	qPCR	Negative
Parvovirus B19)	•	5
HLA typing (HLA-A, B, DR)	PCR-SBT	Consistent with the donor cells
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
Karyotype	G-banding	46,XX[20]
SeV remnants	qPCR	Below the limit of quantification
CNV <sup>(*2)</sup>	WGS, SNP	No de novo CNVs (>1kbp) were found in CDS.
SNV/Indel I <sup>(※3)</sup>	WGS	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.92) and Shibata list <sup>(**4)</sup> .
Undifferentiated markers	Flow cytometry	TRA-1-60(+); 98.8% SSEA4(+); 99.5% TRA-2-49(+); 99.5% OCT3/4(+); 99.8%
Thawed postnatal cells	Counting the number of the cells (**5)	2.13 x 10 <sup>5</sup> cells (Survival rate; 83.3%)
Number of proliferating	Counting the number of the	24.57 × 10 <sup>5</sup> cells (Number of seeded cells;



cells after thawing	cells after culturing for 6	0.65 × 10 <sup>5</sup> cells)
	days <sup>(※6, 7)</sup> .	
Cardiac differentiation	Flow cytometry	Troponin T(+); 64.6%

- (※2) CNV; Copy Number Variation
- (※3) SNV/Indel; Single nucleotide variants /Insertion Deletion
- (¾4) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)
- (%5) NucleoCounter NC-200

## ■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)



Reprint or reproduction of this page without permission is prohibited.